Zealand Pharma A/S (Zealand Pharma A/S) Short-Term Capital Lease Obligation : $2.18 Mil (As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S Short-Term Capital Lease Obligation?

Zealand Pharma A/S's Short-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $2.18 Mil.

Zealand Pharma A/S's quarterly Short-Term Capital Lease Obligation increased from Sep. 2023 ($2.14 Mil) to Dec. 2023 ($2.44 Mil) but then declined from Dec. 2023 ($2.44 Mil) to Mar. 2024 ($2.18 Mil).

Zealand Pharma A/S's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($2.26 Mil) to Dec. 2022 ($2.10 Mil) but then increased from Dec. 2022 ($2.10 Mil) to Dec. 2023 ($2.44 Mil).

Zealand Pharma A/S Short-Term Capital Lease Obligation Historical Data

The historical data trend for Zealand Pharma A/S's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S Short-Term Capital Lease Obligation Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

Get a 7-Day Free Trial

1.14

2.30

2.26

2.10

2.44

Zealand Pharma A/S Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.13	2.15	2.14	2.44	2.18

Zealand Pharma A/S Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Zealand Pharma A/S Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.